Delayed Application of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer (DELAY)

November 13, 2026 updated by: Fabian Acker, Goethe University

Delayed Application of Immune Checkpoint Inhibitors in Patients With Advanced or Metastatic NSCLC Receiving Chemoimmunotherapy

This study is a multicenter, randomized, open-label phase 3 trial of delayed administration of immunotherapy in patients who are planned to receive chemoimmunotherapy for newly diagnosed, advanced or metastatic, PD-L1 positive NSCLC without sensitizing alterations in EGFR, ALK, or ROS1.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

This study enrolls patients with newly diagnosed, PD-L1 positive (PD-L1 TPS ≥ 1%), EGFR/ALK/ROS1-wildtype/-negative, advanced or metastatic non-small cell lung cancer who have not yet received systemic treatment.

Patients are randomized into two treatment arms. In both arms, patients receive standard treatment with histology-guided chemotherapy in combination with the PD-1 inhibitor cemiplimab. Patients in the experimental arm receive chemotherapy on Day 1 and cemiplimab on Day 4 of each cycle. Patients in the control arm receive both therapies on Day 1 of each cycle. After 4 cycles, patients continue with cemiplimab either with or without pemetrexed as per standard of care.

The time interval between chemotherapy and immunotherapy is intended to minimize antagonistic effects of chemotherapy on immunotherapy while simultaneously enhancing potential synergistic effects between the two treatment modalities.

Study Type

Interventional

Enrollment (Estimated)

198

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Hesse
      • Frankfurt am Main, Hesse, Germany, 60590

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Provided written informed consent

  2. Patients must be at least 18 years old

  3. Patients with histologically or cytologically confirmed locally advanced (stage IIIB-C per UICC 9th edition) or metastatic (stage IV) non-small cell lung cancer (NSCLC) who are not candidates for treatment in curative intent including resection and/or definitive chemoradiotherapy, and who have received no prior systemic treatment for recurrent or metastatic NSCLC Note: Patients who received systemic therapies as part of a surgical and/or radiotherapeutic treatment with curative intent (including concomitant, neoadjuvant, adjuvant and/or maintenance therapies) and developed recurrent or metastatic disease more than 12 months after completing therapy are eligible

  4. Positive tumor PD-L1 status defined as PD-L1 tumor proportion score ≥1% (local testing)

  5. No sensitizing alterations in EGFR, ALK or ROS1 (local testing)

  6. At least one (measurable) target lesion according to RECIST version 1.1. Target lesions may be located in a previously irradiated field if there is documented (radiographic) disease progression in that site.

  7. Planned treatment with an anti-PD-(L)1 inhibitor plus platinum-based chemotherapy

  8. Adequate organ function

    1. Hemoglobin ≥ 9g/dl, neutrophil count ≥ 1500/mm³, platelets ≥ 100.000/µL
    2. Estimated glomerular filtration rate (GFR) ≥30ml/min/1.73m²
    3. Bilirubin ≤1.5 x ULN, AST and ALT ≤ 3 x ULN Note: in the case of hepatic involvement, the following criteria apply: Bilirubin ≤3 x ULN, AST and ALT ≤ 5 x ULN
  9. The patient is willing and able to comply with the protocol for the duration of the study, including visits for treatment and scheduled follow-up visits and examinations

Exclusion Criteria:

  1. Symptomatic, neurologically unstable CNS metastases or requiring increasing doses of steroids to manage CNS symptoms within 2 weeks prior to study entry (maximal acceptable dose must be ≤10 mg of prednisolone or equivalent).

    Note: Patients with asymptomatic, incidentally detected CNS metastases may be enrolled. Palliative radiotherapy for asymptomatic brain metastases (and any other, non-brain metastases, e.g. bone metastases) may be conducted after study entry.

  2. Patients with leptomeningeal disease or spinal cord compression

  3. Concurrent enrollment in another interventional trial. Participation in observational studies is acceptable

  4. Presence of cardiovascular disease, as defined by:

    1. New York Heart Association (NYHA) heart failure classifications of class III, or IV; or myocardial infarction, or acute coronary syndrome within 12 months of first dose of study medication; or
    2. Transient ischemic attack or stroke within 1 year
  5. Patients with a history of another malignancy that is either untreated or was treated within the past 3 years, with the exception of malignancies with a low risk of recurrence, such as adequately treated non-melanoma skin cancer, cervical carcinoma in situ, localized prostate cancer or ductal carcinoma in situ. Other similar cases can be considered after discussion with the coordinating investigator

  6. Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts

  7. Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities Exclusion criteria related to autoimmunity, autoinflammation and immunodeficiency

  8. Any condition that requires ongoing/continuous corticosteroid therapy (>10 mg prednisone/day or anti-inflammatory equivalent) within 1 week prior to the first dose of study medication. Participants who require a brief course of steroids (up to 2 days in the week before enrollment) or physiologic replacement are not excluded.

  9. Ongoing or recent evidence of significant autoimmune or inflammatory disease that required treatment with systemic immunosuppressive treatments within the last 2 years.

    Note: The following are not exclusionary: non-bullous skin conditions (e.g., vitiligo), endocrinopathies (such as hypothyroidism or type 1 diabetes) that require only hormone replacement. Other similar cases may be eligible upon consultation with the coordinating investigator.

  10. History of interstitial lung disease (e.g., idiopathic pulmonary fibrosis or organizing pneumonia), of active, non-infectious pneumonitis that required immunosuppressive doses of glucocorticoids to assist with management, or of pneumonitis within the last 5 years. A history of radiation pneumonitis in the radiation field is not exclusionary

  11. History of solid organ or hematopoietic stem cell transplantation. Corneal transplantation is not exclusionary Exclusion criteria relating to infections

  12. Uncontrolled infection with HIV, hepatitis B or hepatitis C infection, diagnosis of immunodeficiency, and/or tuberculosis (active or latent)

    a) Participants with known controlled HIV infection (undetectable viral load on HIV RNA PCR) and CD4 count above 350/µl either spontaneously or on a stable antiviral regimen are eligible. For these participants monitoring will be performed per local standards.

    b) Participants with HBsAg positive who have controlled infection (serum HBV DNA PCR that is below the limit of detection and receiving anti-viral therapy for hepatitis B) are eligible. Participants with controlled infections must undergo periodic monitoring of HBV DNA. Participants must remain on anti-viral therapy for at least 6 months beyond the last dose of investigational study medication.

    c) Participants with HBsAg negative but total HBcAb positive are permitted with the following requirements: If serum HBV DNA PCR is above the limit of detection at screening, initiate HBV antiviral therapy before study entry. If serum HBV DNA PCR is below the limit of detection, periodic monitoring of HBsAg must be performed.

    d) Participants who are HCV Ab+ who have controlled infection (undetectable HCV RNA by PCR either spontaneously or in response to a successful prior course of anti-HCV therapy) are eligible Exclusion criteria relating to vaccines

  13. Receipt of a live vaccine within 4 weeks of start of study medication

  14. Receipt of COVID-19 vaccination within 1 week of planned start of study medication or for which the planned COVID-19 vaccinations would not be completed 1 week prior to start of study medication.

    Exclusion criteria relating to pregnancy and contraception

  15. Women who are pregnant or breast-feeding

  16. WOCBP* and men** who are unwilling to practice highly effective contraception prior to the initial dose/start of the first treatment, during the study, and for at least 4 months after the last dose. Highly effective contraceptive measures include:

    1. Stable use of combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal, transdermal) or progestogen-only hormonal contraception (oral, injectable, implantable) associated with inhibition of ovulation initiated 2 or more menstrual cycles prior to screening;

    2. Intrauterine device; intrauterine hormone-releasing system;

    3. Bilateral tubal occlusion/ligation;

    4. Vasectomized partner (provided that the male vasectomized partner is the sole sexual partner of the WOCBP study participant and that the vasectomized partner has obtained medical assessment of surgical success for the procedure); and/or

    5. Sexual abstinence†,‡. Pregnancy testing and contraception are required for WOCBP. Pregnancy testing and contraception are not required for women who are postmenopausal or permanently sterile.

      • WOCBP are defined as women who are fertile following menarche until becoming postmenopausal, unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy.

      A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high FSH level in the postmenopausal range may be used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient to determine the occurrence of a postmenopausal state. The above definitions are according to the CTFG guidance. Pregnancy testing and contraception are not required for women with documents hysterectomy or tubal ligation.

      **Male participants: A male participant will be excluded from the study if that participant does not agree to use condoms or practice sexual abstinence†‡, unless vasectomized, prior to the initial dose/start of study medication, during the study, and for at least 4 months after the last dose. Sperm donation is also prohibited during the same period. Vasectomy success must be confirmed by semen analysis.

      †Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study drugs. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the participant.

      ‡Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea method are not acceptable methods of contraception. Female condom and male condom should not be used together.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Delayed Chemoimmunotherapy

4 courses of cisplatin/carboplatin D1 + pemetrexed/paclitaxel D1 + cemiplimab D4 every 3 weeks, followed by maintenance cemiplimab ± pemetrexed

Dose per standard-of-care

Dose per standard-of-care

Dose per standard-of-care

Dose per standard-of-care

Dose per standard-of-care

Active Comparator: Concurrent Chemoimmunotherapy

4 courses of cisplatin/carboplatin D1 + pemetrexed/paclitaxel D1 + cemiplimab D1 every 3 weeks, followed by maintenance cemiplimab ± pemetrexed

Dose per standard-of-care

Dose per standard-of-care

Dose per standard-of-care

Dose per standard-of-care

Dose per standard-of-care

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
PFS
Time Frame: max. 60 months

Progression-free survival (PFS), defined as time from randomization until the first documented progression per investigator-assessed RECIST 1.1 criteria or death due to any cause, whichever occurs first

max. 60 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
ORR
Time Frame: max. 60 months

Objective response rate (ORR) is defined as the number of patients achieving a complete or partial response per investigator-assessed RECIST 1.1 criteria as best overall response divided by the number of patients

max. 60 months
OS
Time Frame: max. 60 months

Overall survival (OS) is defined as the time from randomization to the date of death due to any cause

max. 60 months
DOR
Time Frame: max. 60 months

Duration of response per investigator-assessed RECIST 1.1 is defined as the time between the first detection of complete or partial response, whichever occurs earlier, and disease progression or death. DOR will be calculated in patients who achieve a complete or partial response.

max. 60 months
DCR
Time Frame: max. 60 months

Disease control rate (DCR) is defined as the number of patients achieving a complete or partial response or stable disease per investigator-assessed RECIST 1.1 criteria divided by the number of patients

max. 60 months
Frequency and severity of immune-related adverse events (irAEs)
Time Frame: max. 60 months
max. 60 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Fabian Acker, Dr., Goethe University Frankfurt, University Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

February 1, 2027

Primary Completion (Estimated)

February 1, 2032

Study Completion (Estimated)

February 1, 2032

Study Registration Dates

First Submitted

November 9, 2026

First Submitted That Met QC Criteria

November 13, 2026

First Posted (Actual)

November 17, 2026

Study Record Updates

Last Update Posted (Actual)

November 17, 2026

Last Update Submitted That Met QC Criteria

November 13, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.